HiDAC

High-Dose Cytarabine (HiDAC) – Brief Definition

HiDAC (High-Dose Cytarabine) is an intensive chemotherapy regimen used primarily in acute myeloid leukemia (AML) consolidation therapy. It involves:

• Cytarabine (Ara-C) administered at very high doses (typically 3,000 mg/m²).
• Dosing Schedule: Given IV over 3 hours, every 12 hours on days 1, 3, and 5 (total 6 doses per cycle).

Key Features:

• Purpose: Eliminates minimal residual disease (MRD) to prevent relapse.
• Used in:
  • Favorable/intermediate-risk AML (consolidation).
  • Lymphoma (e.g., CNS prophylaxis in high-grade B-cell lymphoma).
• Toxicities:
  • Cerebellar toxicity (ataxia, slurred speech – requires monitoring).
  • Myelosuppression (profound neutropenia/thrombocytopenia).
  • Conjunctivitis (steroid eye drops prophylaxis).

Example:
*”A 52-year-old with AML in remission receives HiDAC (3,000 mg/m² q12h on days 1,3,5) for consolidation, with prophylactic dexamethasone eye drops